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Abstract
For years, it has been assumed that the cerebral accumulation of pathologic protein 
forms is the main trigger of Alzheimer’s disease (AD) pathology; however, recent stud-
ies revealed strong evidences that the alternations in synaptic activity precede and affect 
the homeostasis of amyloid-beta and tau, both of which aggregate during AD. Given 
that the neuropathological changes, characteristic for AD, start decades before the onset 
of the first symptoms, when alternations become irreversible, it is crucial to find a bio-
marker that can detect the preclinical signs of disease, presumably synaptic dysfunction 
of specific cerebral areas. Here is presented a novel, a high potential neuroimaging bio-
marker that can detect the postsynaptic dysfunction of specific neural substrate located 
in medial prefrontal cortex (mPFC) during sensory gating processing of a simple audi-
tory stimulus. The magnetoencephalography-based localization of mPFC gating activa-
tion has the potential not only to detect symptomatic AD but also to become a predictor 
of cognitive decline related to the pathophysiological processes of AD, both at the indi-
vidual level. The strengths of proposed biomarker lie in the simplicity of using a binary 
value, i.e., activated or not activated a neural generator along with its potential to follow 
the evolution of the pathophysiological process of disease from preclinical phase. The 
novel biomarker does not require estimation of uniform cutoff levels and standardiza-
tion processes, the main problems of so far proposed biomarkers. Ability to individually 
detect AD pathology during putative preclinical and clinical stages, absolute noninva-
siveness, and large effect size give this biomarker a high translation capacity and clinical 
potential.
Keywords: Alzheimer’s disease, preclinical Alzheimer’s disease, Alzheimer’s disease 
biomarker, neuroimaging biomarker, auditory sensory gating, prefrontal cortex, 
magnetoencephalography
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1. Introduction
Alzheimer’s disease (AD), a long-lasting progressive neurodegeneration, characterized by 
synaptic dysfunction, an increase in extracellular amyloid plaques, intracellular tauopathy, 
extensive neuronal loss in several cerebral areas, and enhanced neuroinflammation. Highly 
disrupted cholinergic transmission is proving to be a featured biochemical sign of disease. 
Clinical manifestations include progressive loss of ability to encode new memories, impair-
ment of both declarative and non-declarative memory, and finally the invincible decline of 
overall intellectual capacity. Today, worldwide spreading of Alzheimer’s type dementia is 
one of the major public health challenges confronting this generation.
Extensive AD research, especially in the last 40 years, brought a significant progress in the 
development of diagnostic approaches and understanding the etiology. However, despite 
accumulated knowledge, the cause of the disease has not been found, a postmortem histo-
pathological evaluation is still required to confirm the clinical diagnosis, and finally, effective 
treatment that would at least slow progression of the disease has not yet been found. As a 
result, if Augusta Deter, the first patient who had been described with the hallmarks of the 
disease, was alive today, her prognosis would be the same as in 1906.
1.1. Amyloid hypothesis
Since the first documentation by Alois Alzheimer, spread of abnormal protein filaments 
(plaque) throughout the brain, the main histopathological sign of Alzheimer’s dementia, had 
a prominent role in a broad spectrum of proposed mechanisms related to disease pathogen-
esis. Amyloidogenic fragments were described structurally in extracellular plaques, and tau 
protein was documented as the main component of intracellular neurofibrillary tangles [1, 2].
According to amyloid hypothesis, the neurotoxic forms of amyloid-beta polypeptides, 
derived from amyloid precursor protein (APP), induce synaptic injuries followed by sub-
stantial intracellular damage in form of tauopathy and subsequently produce the pathologi-
cal presentations of neurodegeneration leading to dementia [3]. There are reliable evidences, 
provided by the systematic work of Braak and Braak [4, 5], that the pathological progression 
of extracellular and intracellular deposits of pathological protein forms starts decades before 
the onset of clinical symptoms.
The genetic mutations identified on chromosome 21 are conferred to trigger AD through 
abnormal processing of APP, causing the elevated cerebral concentrations of amyloid-beta 
or increased production of its specific forms [6]. Also, three other different autosomal domi-
nant mutations that might cause AD have been identified on chromosomes 14 and 1, lead-
ing to mutations of presenilin 1 and presenilin 2 proteins, respectively, along with late-onset 
apolipoprotein genotype ἐ4 [7–9].
The discoveries of mutations in amyloid-beta-related proteins have had significant influence 
in promoting the amyloid theory. However, while these mutations account for the major-
ity of early-onset AD (<65 years; familial AD), the risk genes linked with late-onset AD 
(> 65 years; 95% of all AD cases) are subtle, with no direct genetic relation to the APP gene or 
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its enzymes [10]. In addition, recent neuroimaging results strongly indicate that some non-
demented individuals can have amyloid-beta aggregates equivalent in concentration to those 
found in demented patients [11], and also symptoms of AD can emerge regardless of amyloid 
deposition [12].
The evidences, provided by the animal studies, that amyloid clearance produces decreased 
symptoms of disease in mouse models of AD [13, 14] had turned the drug development in 
the direction of targeting beta-amyloid in human brains. The deployment of drugs comprised 
active and passive immunization directly against amyloid-beta accumulation and inhibition 
of beta- and gamma-secretase APP cleaving enzyme. Regrettably, none of testing drugs have 
resulted in recovery of functional abilities or alleviating symptoms of the disease in humans. 
The treatments did not slow down the course of the disease; on the contrary, some drugs even 
accelerate the progression of the symptoms. The recently emerged evidences confirmed the 
low correlation of the cerebral distribution of beta-amyloid plaques with neuropathology, 
decrease of neural function, or cognitive deficits [3]. A possibility that insoluble plaque is 
not the primary cause of progressive AD pathology is a strong argument for failure of anti- 
amyloid vaccination trials to improve patient outcome, even when cerebral amyloid plaque 
was removed [15]. Consequently, failure of amyloid-based AD treatments shifts research 
hypothesis to the soluble amyloid beta oligomers rather than plaques to be the main cause of 
neuronal degeneration [16]. However, there is still not reliable evidence in human studies that 
soluble amyloid oligomers are toxic in vivo. Notably, the cause of pathological cascade, result-
ing in redundant amyloid forms production and ejection, is still poorly understood along with 
the issue concerning the role of different amyloid beta forms in AD pathogenesis [17].
1.2. Synaptic function failure hypothesis
Synapse loss generates a loss of dendritic mass [18] and promotes neuron loss [19], a hallmark 
of AD pathology. It is interesting that amyloid plaque can show up without synapse loss [20]; 
moreover, synapse loss can occur without associated amyloid deposition [21]. High quantita-
tive correlations of postmortem cytopathology to premortem cognitive impairments suggest 
that the decrease in density of synapses and decrease in the number of synapses per neuron 
are more linked to AD symptoms than are the concentration of amyloid plaques, the number 
of intracellular tau-tangles, or cortical gliosis [22]. These results appoint synapses as the key 
feature of AD, strongly indicating that the disease pathogenesis could be the outcome of syn-
aptic failure [23].
It has been shown that the early AD symptoms significantly correlate with a specific dys-
function of cholinergic synapses [24]. Interestingly, acetylcholine receptor agonists affect 
several of AD hallmarks, including cholinergic deficits, cognitive dysfunction, but also tau 
and amyloid-beta pathological burdens [25]. The electrophysiological measurements of basal 
synaptic transmission and long-term potentiation in transgenic mouse with mutations analog 
of human mutations causing AD suggest that change in synaptic function precedes amyloid 
plaque production. Increased synaptic activity increases amyloid secretion, while decreasing 
activity inhibits it [26, 27]. In turn, beta-amyloid burden inhibits synapses and alerts syn-
aptic plasticity [28], implying the existence of a feedback loop between synaptic dynamics 
and associated amyloid production that might serve as a mechanism to prevent synaptic 
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hyperactivation and excitotoxicity [26]. In addition, recent studies demonstrate an important 
physiological role of cortical amyloid secretion, showing that low concentrations of beta-
amyloid peptides increase long-term potentiation, needed for successful memory formation 
[29, 30]. There are also evidences that synaptic dysfunction occurs before changes in synaptic 
morphology or the number of synapses per neuron [31, 32]. These breakthroughs in the field 
provide strong evidences that amyloid homeostasis is controlled by the synaptic functions 
and emphasize prominent amyloid involvement in healthy memory coding.
Cerebral dysfunction found in non-demented elderly individuals with amyloid plaques 
before any memory disturbances [33] points at impairment in neural function as a very early 
pathophysiological sign of AD. Interestingly, functional changes may be driven in both direc-
tions, increased [34, 35] or decreased [36, 37] neuronal excitability, usually depending on the 
disease stage and a specific brain area and its function. The increased synaptic activity, found 
in early stages of symptomatic AD, might be an adaptive response driving neuroprotection 
[38]. On the other hand, the decreased neural network excitability could be induced by acti-
vation of gamma-aminobutyric acid (GABA) receptors, which decrease glutamate excitatory 
transmission, implying that in vivo glutamate-mediated neuronal excitability is controlled by 
interactions between inhibitory systems [39]. The co-transmission of acetylcholine and GABA, 
first found within the cholinergic system only, recently was demonstrated as a common fea-
ture of nearly all cholinergic forebrain neurons [40, 41]. These results appoint GABA as a 
fast neurotransmitter utilized throughout the forebrain cholinergic system and emphasized 
acetylcholine-GABA co-release as a major modulation factor of cortical functions transmitted 
by cholinergic neurons. Moreover, there is evidence that GABA receptor agonists defend neu-
rons in culture from the toxicity of beta amyloids and of different glutamate receptor agonists 
[42]. In conclusion, given their major role in both sensory processing and cognition, and high 
susceptibility to AD pathology, the ability of the cholinergic neurons to co-release GABA 
could explain the failure of specific synaptic inhibitory processes found in AD that may trig-
ger the cascade of events resulting in characteristic neuropathology.
1.3. Dynamic model of AD pathogenesis
The presence of cerebral amyloid aggregation in cognitively normal individuals, the lack 
of systematic correlation between amyloid plaque deposition and cognition, insufficiently 
explained influence of soluble amyloid oligomeric in vivo, the bias of preclinical disease mod-
els toward the amyloid hypothesis, and finally failures of clinical trials with anti-amyloid 
drugs are the strong arguments for urgent need to revise present model of AD to include 
alternative possibilities that could account for all the research results associated to AD.
Failures of clinical trials of anti-amyloid drugs in symptomatic AD patients (mild cognitive 
impairment (MCI) and moderate Alzheimer’s disease patients) in addition to reliable evi-
dence that the hallmarks of disease could be found in the brain decades before symptom 
onset set up a view that the onset of clinical symptoms is a sign of irreversible neural damage. 
Consequently, the concept of AD pathogenesis is evolving toward a view of the disease as a 
long-term continuum, which differs only by symptom appearance; that is, a non-symptomatic 
(preclinical) AD phase and an irreversible symptomatic AD phase [43, 44]. This dynamic con-
cept of the disease emphasizes the neurobiological advantage of early intervention before of 
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widespread neurodegeneration, during the preclinical stage of disease, when neural injuries 
may still be reversible. Consequently, it is crucial to detect very early, possibly reversible, 
pathological changes related to AD in cognitively intact individuals, before the occurrence of 
the first symptoms, i.e., to reveal the reliable preclinical biomarker of the disease.
1.4. Conclusion
A wealth of evidence suggests that the amyloid hypothesis of AD etiology is insufficient to 
explain all pathological changes associated with AD and their temporal evolution. Considering 
the wide spectra of data in AD research, it cannot be overlooked their common link: synap-
tic dysfunction and degradation as a very early characteristic of the disease. Unlike neuron 
death, changes in synaptic functions are very likely still reversible. These subtle neurofunc-
tional alternations are likely detectable by functional neuroimaging techniques. The neuro-
imaging has the capability to provide an assessment of the altered neurophysiology, before 
anatomical abnormalities and divergent neuropathology of the later disease stages. Focusing 
the synaptic level, at the phase when the neuron cell potentially is still healthy, provides an 
excellent opportunity to intervene at a reversible stage of the disease when neural networks 
are vulnerable, but not lost. With regard to focal neural activation during the early phases 
of processing external inputs, studying the early sensory responses enable unique insight 
into the synchronized synaptic activity of functionally related neural substrates, which are on 
the larger scale recognized as sensory networks. The first manifestations of declining synap-
tic function could involve desynchronization of synaptic transmission, which may cause the 
“virtual” absence of activation when it is measured extracranially. These alterations in topol-
ogy of sensory networks could be even associated with specific patterns of attention, memory, 
or behavioral disorder that could indicate the preclinical stage of disease.
2. Biomarkers of AD
A biomarker in medicine is conceptualized as a measurable detector of a physiological, ana-
tomic, or biochemical alternation that can distinct normal biologic processes from pathologi-
cal. Biomarker should be able to provide reliable diagnosis, follow the development of disease, 
and measure responses to a therapeutic intervention. The development of a new biomarker 
for any clinical condition is based on the ability to accurately detect specific pathophysiology 
against the gold or reference standard. This creates problem specifically to AD because there 
is no in vivo gold standard. Currently, the final diagnosis of AD requires both the presence of 
amnestic symptoms and postmortem histopathological confirmation. Premortem diagnosis 
of AD is only “probable” or “possible” based on symptoms characteristic of Alzheimer’s type 
of dementia and neuroimaging findings.
The growing body of evidences evolves AD research field toward the concept of disease patho-
genesis as a continuum of long-term phases in which clinical symptomatology and underlying 
pathophysiological process have different temporal development rates [45]. The existing find-
ings indicate that the onset of the first symptoms marked the already irreversible stage of the 
disease [44]. Therefore, only detection of preclinical phase, before the occurrence of the first 
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symptoms, but with present neuropathological changes characteristic of AD, would provide 
a major opportunity for therapeutic intervention in possible still reversible stage of disease. 
The main problem of AD research lies in the fact that is not yet found a solid link between the 
specific biomarker occurrence in presymptomatic individuals and the subsequent appearance 
of clinical symptoms [44, 45]. Although major advances in brain imaging, neurochemistry, and 
genetic research that highly accelerated the field, there still remains a need for the establishment 
of accurate biomarkers of preclinical AD, which will differentiate subjects without the risk of 
progression to dementia from those at risk for developing symptomatic AD. Today, five state-
of-the-art diagnostic measures of AD are proposed for diagnostic criteria [46, 47]. Three of these 
are neuroimaging measures, and the other two are the laboratory indicators related to cerebro-
spinal fluid (CSF) proteins. Laboratory measures of AD include a reduced level of amyloid-beta 
42 or an increase in p-tau concentration in the CSF. Imaging measures include tracers that allow 
detection of fibrillary amyloid-beta deposits in the cortex by positron emission tomography 
(PET) and detectors, also known as injury or topographical biomarkers, of a medial temporal 
lobe atrophy and reduced glucose metabolism in temporoparietal regions, as determined by 
magnetic resonance imaging (MRI) and fluorodeoxyglucose (FDG) PET, respectively. However, 
proposed biomarkers have limited efficiency in detecting preclinical changes associated with 
the disease [45–50] and are invasive for subjects because there are risks associated with lumbar 
puncture (CSF), exposure to radiation (PET/CT), or claustrophobic time-consuming scanning 
(MRI). Moreover, the classification results of proposed biomarkers are based on the difference 
between group means of measured variables that generally cannot provide a clear boundary 
between normal and pathological responses. The underlying reason for the limited discrimina-
tory accuracy of proposed biomarkers lies in the high individual heterogeneity and variability 
of neural responses, cerebral anatomy, and metabolism [51], especially in the elderly popula-
tion. Consequently, there is an urgent need for additional, noninvasive, more accurate tool that 
can be used to differentiate presymptomatic and symptomatic AD from normal aging.
2.1. Topological biomarker of AD
Besides high sensitivity and specificity, ideal AD biomarker should be individual, robust, and 
must be able to follow the evolution of the pathophysiological process of AD from early preclini-
cal changes to symptomatic aggravation of the disease. A promising, but so far underutilized line 
of biomarker research is the alternation of basic neural network topography as a consequence of 
AD pathology [52]. An efficient way to start topographic search for AD biomarker is studying the 
most fundamental, still focal neural mechanisms that occur very early in the processing stream 
of simple sensory inputs. Dominantly cholinergic modulation of a sensory gating processing 
[53, 54] indicates that sensory gating network would likely be alerted in AD pathophysiology 
because the leading neurochemical feature of AD is a deterioration of the cholinergic signal trans-
mission by selective impact on the plasticity of nicotinic (nAChr) and muscarinic (mAChr) syn-
aptic receptors [55]. On a large scale, this synaptic dysfunction is likely to cause subtle alterations 
in sensory gating processing years before meeting criteria for symptomatic AD [56, 57].
2.2. Sensory gating
Sensory gating is a fundamental process of sensory processing, arising within the first 50 
ms of exposure to a stimulus, much earlier than conscious perception. It is a phenomenon 
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by which the neural system rapidly adjusts its response to subsequent stimuli, a neural fea-
ture with an essential impact in everyday life [58, 60]. This fast inhibition or enhancement of 
the neural response provoked by the external stimuli refers to different gating mechanisms: 
by gating-out neural system selectively suppresses its responses to irrelevant or redundant 
stimuli and by gating-in reinforcing responses on task-relevant or novel stimuli [59, 60]. 
Gating-out has been proposed as a mechanism of habituating to redundant stimuli that pro-
tect working memory overload by preventing irrelevant information from recurrent sensory 
processing, while at the same time, gating-in processing enables recognition of relevant envi-
ronment inputs that are essential for survival [59–61].
2.2.1. Clinical correlates of sensory gating
Sensory gating deficits have been associated with several clinical conditions. Patients with 
schizophrenia [62–64], Alzheimer’s disease [60, 64, 65], bipolar disorder [66], post-traumatic 
stress disorder [67], Parkinson’s disease [68], or Huntington’s disease [69] show alerted sen-
sory gating dynamics compared to controls. Abnormality in extracranially measured audi-
tory gating responses is recognized as one of the best established marks for schizophrenia 
[70, 71]. In addition, alerted sensory gating has been associated with impaired performance 
on tasks measuring sustained attention [72], inhibition of distractors [73], or performance on 
neurocognitive tasks [64].
2.2.2. Neurochemistry of sensory gating
Multiple neurotransmitters are found to be involved in sensory gating processing, includ-
ing the cholinergic, dopaminergic, GABAergic, glutamatergic, noradrenergic, and seroto-
nergic systems [74]. Pharmacological studies have emphasized the particular importance of 
the cholinergic system in regulating the decreased response to repeated stimuli (gating-out) 
through stimulation of the α-7 nicotinic receptor [75] and the muscarinic M1 receptor [76]. 
More recently, a marker of the gene for the α-7 nicotinic receptor has been strongly linked to 
sensory gating abnormalities [75]. Notably, α7-containing receptors are also known for fast 
desensitization in the presence of agonist and high Ca2+ permeability [77].
2.2.3. Assessment of sensory gating
Sensory gating is typically assessed using a paired stimulus or oddball paradigm during an 
electrophysiological recording. In a paired-click paradigm, the event-related potential (ERP) 
component P50 or its magnetic counterpart M50, elicited about 50 ms after stimulus presenta-
tion, is measured during the presentation of two identical stimuli (S1 and S2) with an inter-
stimulus interval (ISI) of 500 ms [72, 78]. The habituation of the response to the redundant 
second stimulus, expressed as the ratio between responses amplitudes (S2/S1), indicates the 
strength of gating-out inhibition [79]. Auditory oddball paradigm is characterized by the 
varying occurrence probability of a deviant (novel) stimulus between a series of repeated 
standard stimuli and therefore evokes both gating mechanisms, habituation of redundant 
information (standard stimuli) and pre-attentive memory-based comparison processes 
(deviant stimuli) [60, 64].
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2.2.4. Neuroimaging of sensory gating
Notably, there is a problem in noninvasively studying the gating function in vivo. Only func-
tional neuroimaging technique with millisecond temporal resolution can capture the sensory 
gating dynamics, which occurs within the first 100 ms after stimulus input. Positron emission 
tomography (PET), functional magnetic resonance imaging (fMRI), single-photon emission 
computed tomography (SPECT), and near-infrared spectroscopy (NIRS) are neuroimaging 
techniques that provide indirect look at the brain at work. These techniques provide measures 
of metabolic and vascular signals that are associated with neuronal activity, which are assumed 
to be linearly correlated, although reliable functional relations are not yet established. The 
temporal resolution of these functional techniques is rather low, on a minute scale, compared 
to underlying neural activity, which extends from 1 to 3 ms of action potential firing to a few 
tens of milliseconds of synchronous synaptic activity of thousands of postsynaptic neurons.
Unlike other functional neuroimaging techniques, electroencephalography (EEG) and magne-
toencephalography (MEG) provide a critical opportunity to directly and noninvasively study 
the brain activity [80, 81]. Neurons in the human cortex generally process their information by 
means of electromagnetic signals and thus enable the direct recording of their activity. EEG 
and MEG are electrophysiological techniques that are both sensitive to the electrochemical cur-
rents within and between the brain cells. With sub-millisecond temporal resolution, these tech-
niques can easily capture the dynamics of spontaneous and evoked neural responses. MEG and 
EEG provide a complimentary information about the underlying electromagnetic brain activ-
ity. MEG measures the magnetic field generated by the primary intracellular ionic currents 
through postsynaptic dendrites, while EEG measures the voltage scalp distribution generated 
by the secondary extracellular ionic flow, both produced by the normal brain activity [80, 81].
Though EEG can capture both radial and tangential components of a produced extracellular 
electrical field [80, 81], there was a widely accepted assumption that MEG detects only sources 
that are tangential to the scalp surface. However, recently, it was shown that source orienta-
tion is not a significant factor in limiting MEG sensitivity. Using both numerical simulation 
and empirical measurements, it has been demonstrated that source depth and spatial extent 
of activated assembly on convoluted cortical surface are the main factors that compromise 
the sensitivity of MEG to neural activity in the human cortex [82]. Although both techniques 
have high temporal resolution, MEG outperforms EEG in spatiotemporal localization of neu-
ral substrate underlying extracranially captured electromagnetic activity. Using modern sig-
nal analysis methods the centimeter spatial resolution of EEG approach that of conventional 
fMRI [83]. On the other hand, MEG technique has an excellent, millimeter spatial accuracy 
[82, 84]. Moreover, MEG can detect low-amplitude dipole current source in the deep tissue of 
dislocate cortex, which is simultaneously active with several times higher-magnitude dipole 
sources in the superficial regions of primary sensory areas [60], demonstrating a high spatial 
resolution of synchronously active sources within a neural network. Therefore, MEG can be 
used in two basic ways. The first, similar to the ordinary EEG recordings, utilizes studies 
of rhythmic brain activity, evoked neural processing, and clinical diagnostics to detect the 
presence or signs of abnormality in spontaneous or evoked brain activity. The second and 
more ambitious use of MEG is in the estimation of the location, strength, and time courses of 
neuronal current sources of spontaneous and evoked magnetic signals recorded outside the 
head. In conclusion, MEG is a unique method that enables the noninvasive spatiotemporal 
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mapping of elementary sensory gating processing that rises within first 100 ms after stimulus 
presentation. Moreover, the sources of MEG signals, primarily cortical intracellular postsyn-
aptic currents, make MEG the first choice technique for the noninvasive study of synaptic 
function in real time. Consequently, MEG has an advantage in the neuroimaging search for 
early neurodegenerative biomarkers associated with synaptic alterations.
2.2.5. Cortical network underlying sensory gating
In line with the hierarchical model of neural processing [85], sensory gating responses have 
been long conceptualized to originate in the primary sensory areas [86, 87], due to the very 
early appearance in a sensory process stream. However, a report of the gating response pres-
ence after bilateral damage of the primary auditory areas [88] suggested a contribution from 
at least one source related to arousal level or state [89]. Efforts to delineate the neuroanatomy 
of the sensory gating network long have yielded inconsistent findings [90–93]. The recent 
works, relied on advanced MEG-based multi-dipole source localization, finally provide a reli-
able set of neural generators [60, 64, 94–96]. Moreover, our novel results revealed possible 
explanations concerning the problem of inconsistent reports regarding auditory gating net-
work topology, suggesting that paired-click and oddball paradigms, which are often used to 
challenge sensory gating effects, evoke different gating generator topologies, even though 
they are both passive for the subjects [96].
2.2.6. Auditory sensory gating networks evoked by oddball and paired-click paradigm
Using the oddball paradigm, which evokes both gating-in and gating-out mechanisms, we 
have demonstrated that auditory gating network comprises a medial prefrontal (mPFC) gen-
erator along with the anticipated generators in the bilateral primary auditory cortices [60, 64, 
96], as shown in panel A) of Figure 1. Our finding suggests the existence of a novel, very fast 
sensory processing stream (i.e., sensory gating loop), which links executive PFC to primary 
auditory cortex within the first 50 ms after stimulus presentation, alongside well-affirmed but 
slower limbic (dorsal) and somatic (ventral) sensory processing pathways [60, 96]. The exis-
tence of additional fast sensory processing stream, sensory gating loop, is anatomically sup-
ported by dense bidirectional connections between medial PFC and superior temporal cortices 
found in both primate and human anatomical studies [97, 98]. The mPFC possesses extensive 
cortico-cortical connections, including extensive local projections to and from other prefrontal 
regions, as well as with motor, limbic, and sensory cortices [99]. These structural properties 
of the connecting pathways provide the ability for localized primary auditory generators and 
PFC regions to work together as a large-scale neural network via fast sensory gating loop.
Our novel research provides evidence that passive paired-click and oddball paradigms activate 
a different prefrontal generator within the auditory gating network [60, 96]. Spatiotemporal 
source localization of auditory gating responses evoked by the passive paired-click paradigm 
revealed a different gating topology consisting of a dorsolateral PFC (dlPFC) source in addi-
tion to the sources in the bilateral primary auditory cortices [78, 96], as shown in panel B) 
of Figure 1. This result implies the existence of early rerouting within prefrontal cortex by 
shifting prefrontal gating activation from dorsolateral to medial prefrontal region, depending 
on a paradigm [60, 96], suggesting that mPFC and dlPFC regions serve different functions 
involved during the early sensory processing. A passive paired-click paradigm characterized 
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by the constant repetition of both short- and long-term patterns (S1–500 ms; S2–8 s) could 
result in long-term repetition suppression produced by the dlPFC. On the contrary, an oddball 
paradigm, characterized by the varying occurrence probability of a novel stimulus between a 
series of repeated stimuli, could put the neural network into a state of perceptual expectation 
(gating-in) while simultaneously suppressing redundant stimuli (gating-out). This phenom-
enon could be interpreted as the bottom-up, stimulus-driven initiation of attention during the 
very early sensory processing [100] executed by the mPFC region.
2.2.7. Functional mechanisms underlying auditory sensory gating
In addition to the spatial localization of auditory gating networks, we have disclosed the func-
tional relation within network generators providing strong evidence of a modulatory role 
for the mPFC generator on bilateral superior temporal gyri (STG) sources dynamics during 
gating processing (Figure 2). This result discloses the long-sought mechanism underlying the 
auditory gating effect [60]. We demonstrated the complex form of estimated cortical morphol-
ogy of the neural responses produced by the gating generators. In particular, gating response 
of STG generators is found to be composed of two consecutive cortical subcomponent, Mb1 
peaking at 35–53 ms and Mb2 peaking at 75–95 ms post-stimulus, for both oddball paradigm 
tones [60]. We also provide the first estimates of cortical gating response produced by the 
mPFC generator, which has an analogous tandem form [60], as shown in Figure 2.
Figure 1. Auditory sensory gating network evoked by the oddball paradigm (panel A) and paired-click paradigm (panel 
B). The best-fitting source locations are superimposed on volumetric MRI head data to achieve a spatial (3D) rendering 
of the auditory gating topology. In addition to anticipated bilateral generators in primary auditory areas (blue and green 
dots), both paradigms evoke a prefrontal gating generator (red dot). While oddball tones provoke medial PFC activation, 
the tones of a paired-click paradigm activate dorsolateral PFC areas.
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Taking advantage of the differences in the evoked gating networks between individuals whose 
PFC generator was activated (Type 1 in Figure 2) and cognitively impaired individuals whose 
PFC gating generator was not activated (Type 2 in Figure 2) by the tones of an oddball para-
digm, we have carried out a differential analysis of the functional roles for each generator. 
Our results show that cortical gating dynamics of STG generators evoked by both the stan-
dard and deviant tones demonstrated highly increased strength of both gating components 
in all subjects lacking PFC generator activity [60]. This result is of extreme clinical importance 
because the prevalent view of the gating-related pathologies assumes that the larger ampli-
tude of the extracranial gating response to the standard tone (i.e., redundant stimuli) reflects 
impaired gating out processing of neural substrate in primary auditory areas only (i.e., STG 
generators) [61–63, 66–69]. Our novel results provide strong evidence of sustained inhibitory 
activity of the PFC generator that suppresses or modulates the activity of the STG generators 
as an underlying mechanism of both gating phenomena. Consequently, impaired activity of a 
PFC gating generator could be a primary cause of impaired extracranially measured sensory 
gating responses, found in numerous neurological and psychological clinical conditions.
3. Link between impaired sensory gating and AD pathology
The initial symptoms of AD include subtle decline of the ability to learn new information along 
with diverse amnestic disorders without present brain injuries. Clinically indicated AD signs 
are pointing to the existence of functional impairment of synapses that are involved in convert-
ing and forming new declarative memory [32]. Whereas longer retention of sensory memory 
traces derive more successful memory encoding [101], sensory gating process, conceptualized 
Figure 2. Estimated cortical dynamics of auditory gating network generators evoked by the oddball paradigm. Cortical 
dynamics of medial prefrontal (PF) and STG gating generators for both tones (standard and deviant) are shown for 
eight representative subjects (four of each network type). Gating network type 1 comprised bilateral STG and the PF 
source, while network type 2 was characterized by the absence of PF activation. The time courses of the STG activity 
were individually averaged across hemispheres and displayed for 30–200 ms time window to include M100, the most 
prominent STG response, for the amplitude comparison with earlier Mb1 and Mb2 components. Both components of 
STG gating response (Mb1 and Mb2) are significantly increased when PF source activation is absent.
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as the ability of the neural system to modulate its responses to subsequent stimuli, has a fun-
damental role in guiding successful encoding of new information. Impaired auditory gating 
processing may reduce pre-attentive signal-to-noise ratio and desynchronize synaptic consoli-
dation in the initial phases of memory formation [58]. Augmentation of dysfunctional sensory 
gating process could yield to the first amnestic symptoms seen in AD neuropathology.
A range of EEG/MEG studies, measuring evoked sensory responses, have reported differ-
ences in early processing of auditory [102–104] stimuli in symptomatic AD patients, affirming 
the possibility of impaired inhibition of redundant information (gating-out) and processing of 
novel information (gating-in) in the initial phase of disease. Also, alerted connectivity among 
different brain regions and decline of long-distance synchronization are found to be respon-
sible for some of the earliest cognitive changes in early phases of symptomatic AD [105]. 
Although the study of the extracranial neurophysiological (EEG/MEG) signals provides 
valuable information regarding the pathology-related changes in the amplitudes, latencies, 
frequency bands, spectral densities, and coherence of oscillatory brain dynamics, identified 
relations have received limited attention in the search for a biomarker of AD. The main reason 
is that classification based on the difference between group means of sensor-level measures 
generally cannot provide a clear individual boundary value between healthy and pathological 
responses and thus result in lower clinical significance. However, MEG spatiotemporal local-
ization of cortical sources underlying extracranial magnetic field shows internal consistency 
and provides highly reliable and stable results of both cortical dynamics and topology of the 
activated network [60, 82, 84], enabling a search for an AD biomarker at the individual level.
3.1. Localization of auditory gating network generators: a topological biomarker  
of AD
Using MEG spatiotemporal source calculations, we have demonstrated [64] the potential of 
topological localization of mPFC generator within an auditory gating network as a discrete, 
binary, noninvasive tool for detection of AD at the individual subject level. We found three types 
of gating network topologies evoked by a simple auditory oddball paradigm across the research 
sample of elderly individuals, ranging from 63 to 87 years of age, which comprised patients 
with clinical diagnosis of symptomatic AD (MCI and moderate AD) and non-symptomatic 
elderly controls. Discrete localization/non-localization of mPFC gating generator absolutely dis-
criminate symptomatic AD from controls confirm the indiscernibility between amnestic MCI 
(aMCI) and AD patients and differentiate two distinct gating network types within the elderly 
controls, one of which is suggested as preclinical AD. The lack of mPFC generator localization 
within an auditory gating network as a biomarker of symptomatic AD shows a large effect size 
(>0.9) and high accuracy, sensitivity, and specificity (100%) in respect of clinical diagnosis [64].
3.2. Sustained activation of mPFC gating generator: a sign of healthy cognitive aging
We have applied spectra of the multivariate analyses to disclose potentially hidden structure 
in complete set of our data, i.e., scores of wide neuropsychological screening and neurophysi-
ological gating network topology results [64]. Clustering based on principal variables indi-
cated the existence of three stable clusters across subjects as shown in Figure 3. Subsequent 
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statistical review of group differences on neuropsychological tests confirmed the low- 
magnitude but significant differences in Mini Mental State Exam (MMSE) and delayed Rey-
Osterreith Complex Figure Test (dROCFT) scores across subjects in different cluster groups 
[64]. The first group of controls, characterized by sustained gating activation of mPFC genera-
tor for both oddball tones, had the highest MMSE scores and the highest performance on the 
dROCFT, thus considered to be cognitively healthy elderly group.
3.3. Partial activation of mPFC gating generator: a biomarker of preclinical AD
The second cluster group of controls was characterized by the first signs of neurophysiologi-
cal gating alternation, which emerged as a partial activation of the mPFC gating generator to 
the deviant tone only, as shown in Table 1. The standard tone did not evoke mPFC activation, 
suggesting that a very early stage of impairment in sensory gating processing is manifested by 
an absence of mPFC gating transmission that corrupts habituation to redundant stimuli [64]. 
We confirmed the presence of insidious cognitive decline in this subgroup of controls, dem-
onstrating the low-amplitude but significantly lower both MMSE and dROCFT scores in com-
parison with the high-functioning subgroup of controls [64]. Overall, both neuropsychological 
and neurophysiological impairments characteristic of an AD type of dementia found in low-
functioning control group, although they did not yet meet clinical criteria for aMCI, indicate 
a possible preclinical AD phase. The additional weight to our speculation gave Takayama, 
Figure 3. Dendrogram based on the neuropsychological and neurophysiological variables. Subjects were assigned 
numbers from 1 to 20 and grouped into clusters. Variables were normalized before using a clustering algorithm with 
Ward’s minimum variance method as amalgamation rule and with Euclidean distance as a measure of dissimilarity. 
Cluster grouping disclosed three groups across two clinical categories (H-healthy subjects, MCI/AD—symptomatic AD 
subjects) suggesting the potential of the proposed approach to detect subgroup of control (“healthy”) subjects who are 
in the possible preclinical phase of AD (cluster category 2).
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whose 10-year longitudinal study also discerns the dROCF test as highly assertive indicator 
of conversion to symptomatic phase of Alzheimer’s disease, i.e., found significant sensitivity 
of dROCFT scores to early, possible preclinical AD pathology [106].
The possibility that partial gating activation of the mPFC generator in lower-functioning con-
trols may be associated with preclinical AD phase is also confirmed by several recent find-
ings. There are evidences that reduced functional connectivity affecting the PFC is associated 
with amyloid-β-related hypersynchronization [107] and p-tau pathology [108] in a very early 
phase of AD-type memory impairment. The impaired mPFC activity during endogenous 
brain activity or memory tasks is found in cognitively normal individuals who were AD 
APOE ε 4 carriers [109]. Also, evidence of decreased extracranial gating dynamics as a predic-
tor of cerebrospinal amyloid-β reduction is demonstrated in MCI patients [65]. Alerted synap-
tic function along with subsequent synaptic loss and transneuronal spread of pathological tau 
forms [108] through PFC regions could result in the topological gating deficit that we found in 
a low-functioning subgroup of controls. This topological gating deficit could reflect a possible 
preclinical phase of AD pathology before widespread of cognitive symptoms.
Subject MMSE dROCFT mPFC standard mPFC deviant Clinical diagnosis Cluster category
S1 30 26 1 1 H 1
S2 30 25 1 1 H 1
S3 30 23 1 1 H 1
S4 30 23 1 1 H 1
S5 30 22 0 1 H 2
S6 30 22 0 1 H 2
S7 30 17 0 1 H 2
S8 29 26 0 1 MCI 2
S9 29 25 0 1 H 2
S10 29 18 0 1 H 2
S11 26 20 0 1 H 2
S12 26 12 0 0 MCI 3
S13 26 7 0 0 MCI 3
S14 26 1.5 0 0 MCI 3
S15 25 13 0 0 MCI 3
S16 25 0 0 0 AD 3
S17 25 0 0 0 AD 3
S18 24 10.5 0 0 AD 3
S19 23 0 0 0 AD 3
S20 22 2 0 0 AD 3
Table 1. Subject scores on the MMSE, dROCFT, mPFC gating generator activation (1-activated, 0-non-activated), clinical 
diagnosis, and cluster group.
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3.4. Complete absence of mPFC gating generator activation: a biomarker of 
symptomatic AD
Subjects within the cluster group characterized by the complete absence of mPFC gating gen-
erator activation regardless of the tone condition (i.e., standard and deviant tone) had the 
lowest neuropsychological test results and belonged to the symptomatic AD patients with 
clinical diagnosis [64], as shown in Figure 3. Clearly, a topological deficit of mPFC gating gen-
erator activation is augmented in symptomatic AD phase, taking place during both gating out 
(inhibition of standard tone) and gating in (enhanced processing of novel tone), suggesting 
complete disruption of sensory gating process. This absolute break of a fundamental sensory 
process is associated with the onset of the amnestic AD symptoms. It is possible that progres-
sive failure in sensory gating-out, found in possible preclinical phase of disease, is likely to 
lead to an overload of working memory due to noise accretion and consequent to the first 
symptoms of memory impairment.
There are numerous evidences of association between symptomatic AD pathology and alerted 
physiology of PFC region. Decreased frontal-parietal correlations of glucose metabolism [110], 
prefrontal glucose hypometabolism on 18F-fluorodeoxyglucose PET scans [111], and frontal 
retention of 11C-Pittsburgh compound [112] are found in AD patients. Klupp and colleagues 
[113] found a significant hypometabolism in PFC regions that are not loaded with amyloid 
plaques, suggesting that the deficit in mPFC gating activation may be related to longitudi-
nal amyloid deposition in different but functionally connected brain regions. For instance, 
absence or desynchronization of mPFC gating activity could induce atrophy across fast audi-
tory sensory gating loop, which may result in increased amyloid vulnerability of synapses 
terminated within primary auditory areas involved in the gating process. Inactivity of the 
mPFC generator during processing of repetitive stimuli (gating-out) likely impairs the abil-
ity to distinguish novel from repetitive information, which is critical for long-term memory 
encoding. It has been demonstrated that activation of presynaptic α-7-nAChRs, involved in 
gating transmission, induces long-term potentiation of the excitatory input [114]. Therefore, 
a topological deficit of mPFC generator activation during gating transmission could be a 
consequence of impaired nAChR levels found in PFC regions of AD patients. Alerted function 
of α-7-nAChRs could induce lower levels of intracellular calcium, consequently impairing the 
calcium cascade in producing synchronized postsynaptic signals required for effective both 
gating processing and long-term memory encoding.
4. Conclusion
Identification of a novel biomarker of AD (Figure 4) with the potential to detect both puta-
tive preclinical and clinical stages at the individual subject level represents significant prog-
ress toward improving diagnosis of AD and accelerating the field toward the neurobiological 
advantage of earlier intervention. Although the study engaged only a research sample, the 
very large effect size (>0.98) of proposed test, thanks to its binary nature, provides high rel-
evance to the finding. Such a large effect size enables this study with the research sample size 
to yield power greater than 85%.
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Figure 4. Proposed topological approach as biomarker of AD pathology. Three distinct types of mPFC auditory gating 
generator activation (red dot) were identified in healthy controls, possible preclinical AD and symptomatic AD patients. 
The healthy gating topology type requires mPFC activation in processing both oddball tones (standard and deviant). An 
altered gating topology, characterized by selective mPFC activation only by the deviant tone, presumably represents a 
presymptomatic phase of AD. Symptomatic AD gating topology lacks mPFC activation for both standard and deviant 
tones.
Novel topological biomarker, besides high accuracy, sensitivity, and specificity (100%) in 
identifying symptomatic AD patients in the research sample, shows the potential of follow-
ing the evolution of the pathophysiological process of disease. The noninvasiveness and low 
sensitivity to individual heterogeneity and variability due to the discrete nature of impaired 
prefrontal gating activation are the most important properties of the novel biomarker. It is not 
based on the use of group means and is not associated with statistically significant changes in 
a continuous variable. The advantage of this biomarker lies in the simplicity of using a binary 
value, i.e., activated or not activated a prefrontal generator during gating processing of simple 
tones. The proposed biomarker is absolutely noninvasive; it is based on recordings of neuro-
magnetic fields that are produced by normal brain activity.
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The new topographic tool certainly has properties, which place it within a group of high-
potential biomarkers. The absolute noninvasiveness, individual detection of pathology, 
ability to detect the preclinical phase of the disease, discrete nature that does not require 
estimation of uniform cutoff levels and standardization processes, the low sensitivity to indi-
vidual heterogeneity and variability, capability to follow the evolution of the pathophysi-
ological process of AD, and finally high accuracy and sensitivity make it highly promising 
biomarker of AD.
However, despite mentioning highlights, the proposed biomarker requires to be tested in 
a large independent sample and requires assessment in longitudinal clinical MEG studies 
that would track nonsymptomatic elderly with partial activation of the prefrontal gating 
generator until the first clinical symptoms appear and finally to autopsy for confirmation of 
AD. It would also be necessary to investigate prefrontal gating dynamics in other dementias 
to determine the specificity of novel biomarker to discriminate AD from other etiologies of 
age-related cognitive decline.
Author details
Sanja Josef Golubic
Address all correspondence to: sanja.phy@net.hr
Department of Physics, Faculty of Science, University of Zagreb, Croatia
References
[1] Roher A, Wolfe D, Palutke M, KuKuruga D. Purification, ultrastructure, and chemical 
analysis of Alzheimer disease amyloid plaque core protein. Proceedings of the National 
Academy of Sciences of the United States of America. 1986;83:2662-2666
[2] Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-
associated protein tau. A component of Alzheimer paired helical filaments. The Journal 
of Biological Chemistry. 1986;261:6084-6089
[3] Morris GP, Clark IA, Vissel B. Inconsistencies and controversies surrounding the amyloid 
hypothesis of Alzheimer's disease. Acta Neuropathologica Communications. 2014;2:135
[4] Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta 
Neuropathologica. 1991;82:239-259
[5] Braak H, Braak E. Staging of Alzheimer’s disease-related neurofibrillary changes. 
Neurobiology of Aging. 1995;16:271-278
[6] Bird TD. Genetic factors in Alzheimer’s disease. The New England Journal of Medicine. 
2005;352:862-864
Topological Biomarker of Alzheimer’s Disease
http://dx.doi.org/10.5772/intechopen.76633
185
[7] Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses 
AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the 
risk of Alzheimer’s disease in late onset families. Science. 1993;261:921-923
[8] Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, et al. Cloning of a gene 
bearing missense mutations in early-onset familial Alzheimer’s disease. Nature. 
1995;375:754-760
[9] Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, et al. Familial Alzheimer’s 
disease in kindreds with missense mutations in a gene on chromosome 1 related to the 
Alzheimer’s disease type 3 gene. Nature. 1995;376:775-778
[10] Thies W, Bleiler L. Alzheimer's disease facts and figures. Alzheimer's and Dementia. 
2011;7:208-244
[11] Rentz DM, Locascio JJ, Becker JA, Moran EK, Eng E, Buckner RL, Sperling RA, Johnson KA. 
Cognition, reserve, and amyloid deposition in normal aging. Annals of Neurology. 2010;67: 
353-364
[12] Tsai J, Grutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local syn-
aptic abnormalities and breakage of neuronal branches. Nature Neuroscience. 2004;7: 
1181-1183
[13] Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, et al. Immunization with amy-
loid-[beta] attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 
1999;400:173-177
[14] Lobello K, Ryan JM, Liu E, Rippon G, Black R. Targeting beta amyloid: A clinical review 
of immunotherapeutic approaches in Alzheimer’s disease. International Journal of 
Alzheimer's Disease. 2012;2012:628070
[15] Mullane K, Williams M. Alzheimer's therapeutics: Continued clinical failures question 
the validity of the amyloid hypothesis-but what lies beyond? Biochemical Pharmacology. 
2013;85:289-305
[16] Ferreira ST, Klein WL. The Aβ oligomer hypothesis for synapse failure and memory loss 
in Alzheimer’s disease. Neurobiology of Learning and Memory. 2011;96:529-543
[17] Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer's disease: 
An emperor in need of clothes. Nature Neuroscience. 2012;15:349-357
[18] Uylings HBM, de Brabander JM. Neuronal changes in normal human aging and 
Alzheimer's disease. Brain and Cognition. 2002;49:268-276
[19] Conforti L, Adalbert R, Coleman MP. Neuronal death: Where does the end begin? 
Trends in Neurosciences. 2007;30:159-166
[20] Boncristiano S, Calhoun ME, Howard V, Bondolfi L, Kaeser SA, Wiederhold KH, 
Staufenbiel M, Jucker M. Neocortical synaptic Bouton number is maintained despite 
robust amyloid deposition in APP23 transgenic mice. Neurobiology of Aging. 2005; 
26:607-613
Biomarker - Indicator of Abnormal Physiological Process186
[21] Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, 
Hyman BT. Dendritic spine abnormalities in amyloid precursor protein transgenic mice 
demonstrated by gene transfer and intravital multiphoton microscopy. The Journal of 
Neuroscience. 2005;25:7278-7287
[22] Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of 
cognitive alternations in Alzheimer’s disease: Synapse loss is the major correlate of cog-
nitive impairment. Annals of Neurology. 1991;30:572-580
[23] Mesulam MM. A plasticity-based theory of the pathogenesis of Alzheimer's disease. 
Annals of the New York Academy of Sciences. 2000;924:42-24
[24] Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM. Alzheimer’s disease: Targeting 
the cholinergic system. Current Neuropharmacology. 2016;14(1):101-115
[25] Cacamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM. M1 
receptors play a central role in modulating AD-like pathology in transgenic mice. 
Neuron. 2006;49(5):671-682
[26] Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, et al. APP process-
ing and synaptic function. Neuron. 2003;2003, 37:925-937
[27] Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, et al. Synaptic activity 
regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913-922
[28] Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-
beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity 
and memory. Nature Medicine. 2008;14:837-842
[29] Puzzo D, Privitera L, Fa M, Staniszewski A, Hashimoto G, Aziz F, et al. Endogenous 
amyloid-beta is necessary for hippocampal synaptic plasticity and memory. Annals of 
Neurology. 2011;69:819-830
[30] Garcia-Osta A, Alberini CM. Amyloid beta mediates memory formation. Learning & 
Memory. 2009;16:267-272
[31] Watase K, Weeber EJ, Antalffy B, Yuva-Payor L, Hashimoto K, Kano M, Atkinson R, Sun 
Y, Armstrong DL, Sweatt JD, Orr HT, Paylor R, Zoghby HY. A long CAG repeat in the 
mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility 
on selective neurodegeneration. Neuron. 2002;34:905-919
[32] Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789-791
[33] Sperling RA, Laviolette PS, O’Keefe K, O’Brien J, Rentz DM, Pihlajamaki M. Amyloid 
deposition is associated with impaired default network function in older persons with-
out dementia. Neuron. 2009;63:178-188
[34] Reiman EM. QuirozYT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez Del-Rio M, et al. 
Brain imaging and fluid biomarker analysis in young adults at genetic risk for auto-
somal dominant Alzheimer’s disease in the presenilin1 E280A kindred: Acase-control 
study. Lancet Neurology. 2012;11:1048-1056
Topological Biomarker of Alzheimer’s Disease
http://dx.doi.org/10.5772/intechopen.76633
187
[35] Marchetti C, Marie H. Hippocampal synaptic plasticity in Alzheimer’s disease: What 
have we learned so far from transgenic models? Reviews in the Neurosciences. 
2011;22:373-402
[36] Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O. Progressive age-related 
development of Alzheimer-like pathology in APP/PS1 mice. Annals of Neurology. 
2004;55:801-814
[37] Menkes-Caspi N, Yamin HG, Kellner V, Spires-Jones TL, Cohen D, Stern EA. Pathological 
tau disrupts ongoing network activity. Neuron. 2015;85:959-966
[38] Tampellini D. Synaptic activity and Alzheimer’s disease: A critical update. Frontiers in 
Neuroscience. 2015;9:423
[39] Rodriguez Manzanares PA, Isoardi NA, Carrer HF, Molina VA. Previous stress facili-
tates fear memory, attenuates GABAergic inhibition, and increases synaptic plasticity in 
the rat basolateral amygdala. The Journal of Neuroscience. 2005;25(38):8725-8734
[40] Lee S, Kim K Zhou ZJ. Role of ACh-GABA cotransmission in detecting image motion 
and motion direction. Neuron. 2010;68:1159-1172
[41] Saunders A, Granger AJ, Sabatini BL. Corelease of acetylcholine and GABA from cholin-
ergic forebrain neurons. eLife. 2015;4:e06412. DOI: 10.7554/eLife.06412
[42] Paula-Lima AC, De Felice FG, Brito-Moreira J, Ferreira ST. Activation of GABA(A) recep-
tors by taurine and muscimol blocks the neurotoxicity of beta-amyloid in rat hippocam-
pal and cortical neurons. Neuropharmacology. 2005;49:1140-1148
[43] Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L. Mild cog-
nitive impairment represents early-stage Alzheimer disease. Archives of Neurology. 
2001;58:397-405
[44] Sperling RA, Aisen PS, Beckett LA, Bennet DA, Craft D, et al. Toward definig the preclin-
ical stages of Alzheimer's disease: Recommendetation from national institute on aging- 
Alzheimer's Asocciation workgroup on diagnostic guidelines for Alzheimer's disease. 
Alzheimer's Dementia. 2011;7(3):280-292
[45] Lazarczyk MJ, Hof PR, Bouras C, Giannakopoul P.  Preclinical Alzheimer disease: iden-
tification of cases at risk among cognitively intact older individuals. BMC Medicine. 
2012;10:127. doi.org/10.1186/1741-7015-10-127
[46] Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P. Preclinical Alzheimer 
disease: Identification of cases at risk among cognitively intact older individuals. BMC 
Medicine. 2012;10:127. doi.org/10.1186/1741-7015-10-1276
[47] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, et al. The diagno-
sis of dementia due to Alzheimer’s disease: Recommendations from the national insti-
tute on aging and the Alzheimer’s Association Workgroup. Alzheimer's & Dementia. 
2011;7:263-269
[48] Morris JC, Blennow K, Froelich L, Nordberg A, Soininen H, Waldemar G, Wahlund LO, 
Dubois B. Harmonized diagnostic criteria for Alzheimer's disease: Recommendations. 
Journal of Internal Medicine. 2014;275(3):204-213
Biomarker - Indicator of Abnormal Physiological Process188
[49] Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right 
stage. Science Translational Medicine. 2011;3(111):111-133
[50] Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: The challenge of the second 
century. Science Translational Medicine. 2011;3(77):77sr1
[51] Poulson RS, Gadbury L, Allison DB. Treatment heterogeneity and individual qualitative 
interaction. The American Statistician. 2012;66(1):16-24
[52] Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, 
Vemuri P, Wiste HJ, Weigand SD, et al. Tracking pathophysiological processes in 
Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet 
Neurology. 2013;12:207-216
[53] Adler LE, Hoffer LJ, Griffith J, Waldo MC, Freedman R. Normalization by nicotine of 
deficient auditory sensory gating in the relatives of schizophrenics. Biological Psychiatry. 
1992;32:607-616
[54] Lucas-Meunier E, Fossier P, Baux G, Amar M. Cholinergic modulation of the cortical 
neuronal network. Pflügers Archiv. 2003;446:17-29
[55] Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: 
Behavioral characterization, pharmacological specification, and anatomic localization. 
Psychopharmacology. 2006;184:523-539
[56] Palop JJ, Mucke L. Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: 
From synapses toward neural networks. Nature Neuroscience. 2010;13:812-818
[57] Knafo S, Sánchez-Puelles C, Palomer E, Delgado I, Draffin JE, et al. PTEN recruitment 
controls synaptic and cognitive function in Alzheimer's models. Nature Neuroscience. 
2016;19(3):443-453
[58] Freedman R, Adler LE, Myles-Worsley M, Nagamoto HT, Miller C, et al. Inhibitory gat-
ing of an evoked response to repeated auditory stimuli in schizophrenic and normal 
subjects. Human recordings, computer simulation, and an animal model. Archives of 
General Psychiatry. 1996;53:1114-1121
[59] Gjini K, Arfken C, Boutros NN. Relationships between sensory “gating out” and sensory 
“gating in” of auditory evoked potentials in schizophrenia: A pilot study. Schizophrenia 
Research. 2010;121:139-145
[60] Josef Golubic S, Aine CJ, Stephen JM, Adair JC, Knoefel JE, Supek S. Modulatory role of 
the prefrontal generator within the auditory M50 network. NeuroImage. 2014;92:120-131
[61] Boutros NN, Torello MW, Barker BA, Tueting PA, Wu SC. The P50 evoked potential 
component and mismatch detection in normal volunteers: Implications for the study of 
sensory gating. Psychiatry Research. 1995;57:83-88
[62] Patterson JV, Hetrick WP, Boutros NN, Jin Y, Sandman C, Stern H, Potkin S, Bunney 
WE Jr. P50 sensory gating ratios in schizophrenics and controls: A review and data 
analysis. Psychiatry Research. 2008;158(2):226-247
Topological Biomarker of Alzheimer’s Disease
http://dx.doi.org/10.5772/intechopen.76633
189
[63] Yee CM, Williams TJ, White PM, Nuechterlein KH, Ames D, Subotnik KL. Attentional 
modulation of the P50 suppression deficit in recent-onset and chronic schizophrenia. 
Journal of Abnormal Psychology. 2010;119(1):31-39
[64] Josef Golubic S, Aine CJ, Stephen JM, Adair JC, Knoefel JE, Supek S. MEG biomarker of 
Alzheimer's disease: Absence of a prefrontal generator during auditory sensory gating. 
Human Brain Mapping. 2017;38(10):5180-5194
[65] Green DL, Payne L, Polikar R, Moberg PJ, Wolk D, Kounios J. P50: A candidate ERP bio-
marker of prodromal Alzheimer's disease. Brain Research. 2015;624:390-397
[66] Wang Y, Feng Y, Jia Y, Wang W, Xie Y, Guan Y, Zhong S, Zhu D, Huang L. Auditory M50 
and M100 sensory gating deficits in bipolar disorder: A MEG study. Journal of Affective 
Disorders. 2014;152-154:131-138
[67] Neylan TC, Fletcher DJ, Lenoci M, McCallin K, Weiss DS, Schoenfeld FB, Fein G. Sensory 
gating in chronic posttraumatic stress disorder: Reduced auditory P50 suppression in 
combat veterans. Biological Psychiatry. 1999;46:1656-1664
[68] Teo C, Rasco L, al-Mefty K, Skinner RD, Boop FA, Garcia-Rill E. Decreased habituation 
of midlatency auditory evoked responses in Parkinson's disease. Movement Disorders. 
1997;12(5):655-664
[69] Uc EY, Skinner RD, Rodnitzky RL, Garcia-Rill E. The midlatency auditory evoked 
potential P50 is abnormal in Huntington's disease. Journal of the Neurological Sciences. 
2003;212:1-5
[70] Adler LE, Pachtman E, Franks RD, Pecevich MC, Waldo M, Freedman R. Neuro-
physiological evidence for a defect in neuronal mechanisms involved in sensory gating 
in schizophrenia. Biological Psychiatry. 1982;17:639-655
[71] Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S. Meta-analysis of the P300 
and P50 waveforms in schizophrenia. Schizophrenia Research. 2004;70:315-329
[72] Potter D, Summerfelt A, Gold J, Buchanan RW. Review of clinical correlates of P50 
sensory gating abnormalities in patients with schizophrenia. Schizophrenia Bulletin. 
2006;32(4):692-700
[73] Erwin RJ, Turetsky BI, Moberg P, Gur RC, Gur RE. P50 abnormalities in schizophre-
nia: Relationship to clinical and neuropsychological indices of attention. Schizophrenia 
Research. 1998;33:157-167
[74] Adler LE, Olincy A, Waldo M, et al. Schizophrenia, sensory gating, and nicotinic recep-
tors. Schizophrenia Bulletin. 1998;24:189-202
[75] Freedman R, Leonard S, Gault JM, et al. Linkage disequilibrium for schizophrenia at the 
chromosome 15q13-14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene 
(CHRNA7). American Journal of Medical Genetics. 2001;105:20-22
[76] Klinkenberg IPM, Blokland AAJ, Riedel WJ, Sambeth A. Cholinergic modulation of 
auditory processing, sensory gating and novelty detection in human participants. 
Psychopharmacology. 2013;225(4):903-921
Biomarker - Indicator of Abnormal Physiological Process190
[77] Castro NG, Albuquerque EX. Alpha-Bungarotoxin-sensitive hippocampal nicotinic 
receptor channel has a high calcium permeability. Biophysical Journal. 1995;68(2): 
516-524
[78] Josef Golubic S, Susac A, Huonker R, Haueisen J, Supek S. Early attentional modulation 
of the neural network evoked with the auditory paired-click paradigm: An MEG study. 
Procedia-Social and Behavioral Sciences. 2014;126:195-196
[79] Freedman R, Adams CE, Adler LE, Bickford PC, Gault J, Harris J, Leonard S. Inhibitory 
neurophysiological deficit as a phenotype for genetic investigation of schizophrenia. 
American Journal of Medical Genetics. 2000;97:58-64
[80] Baillet S, Mosher JC, Leahy RM. Electromagnetic brain mapping. IEEE Signal Processing 
Magazine. 2001;18:14-30
[81] Barkley GL. Controversies in neurophysiology. MEG is superior to EEG in localization 
of interictal epileptiform activity. Pro. Clinical Neurophysiology. 2004;115(5):1001-1009
[82] Josef Golubic S, Susac A, Grilj V, Ranken D, Huonker R, Haueisen J, Supek S. Size matters: 
MEG empirical and simulation study on source localization of the earliest visual activity 
in the occipital cortex. Medical & Biological Engineering & Computing. 2011;4:545-554
[83] Michel CM, Murray MM, Lantz G, Gonzalez S, Spinelli L, Grave de Peralta R. EEG 
source imaging. Clinical Neurophysiology. 2004;115(10):2195-2222
[84] Supek S, Stingl K, Josef Golubic S, Susac A, Ranken D. Optimal spatio-temporal matrix sub-
division for cortical neurodynamics estimation. In: Proceedings of the 15th International 
Conference on Biomagnetism (BIOMAG 2006); Vancouver. 2006. pp. 180-181
[85] Felleman DJ, Van Essen DC. Distributed hierarchical processing in the primate cerebral 
cortex. Cerebral Cortex. 1991;1:1-147
[86] Lu BY, Edgar JC, Jones AP, Smith AK, Huang MX, Miller GA, Canive JM. Improved test–
retest reliability of 50 ms paired-click auditory gating using magnetoencephalopgaphy 
source modeling. Psychophysiology. 2007;44:86-90
[87] Edgar JC, Huang MX, Weisend MP, Sherwood A, Miller GA, Adler LE, Canive JM. 
Interpreting abnormality: An EEG and MEG study of P50 and the auditory paired-stim-
ulus paradigm. Biological Psychology. 2003;65:1-20
[88] Woods DL, Knight RT, Neville HJ. Bitemporal lesions dissociate auditory evoked 
potentials and perception. Electroencephalography and Clinical Neurophysiology. 
1984;57:208-220
[89] Korzyukova O, Pfliegere ME, Wagnerf M, Bowyer SM, Rosburgb T, Sundaresana K, 
Elgerb CE, Boutros NN. Generators of the intracranial P50 response in auditory sensory 
gating. NeuroImage. 2007;35:814-826
[90] Reite M, Teale P, Zimmerman J, Davis K, Whalen J. Source localization of a 50 msec 
latency auditory evoked field component. Electroencephalography and Clinical Neuro-
physiology. 1988;70:490-498
Topological Biomarker of Alzheimer’s Disease
http://dx.doi.org/10.5772/intechopen.76633
191
[91] Thoma RJ, Hanlon FM, Moses SN, et al. M50 sensory gating predicts negative symp-
toms in schizophrenia. Schizophrenia Research. 2005;73:311-318
[92] Grunwald T, Boutros NN, Pezer N, von Oertzen J, Fernandez G, Schaller C, Elger CE. 
Neuronal substrates of sensory gating within the human brain. Biological Psychiatry. 
2003;53:511-519
[93] Boutros NN, Trautner P, Rosburg T, Korzyukov O, Grunwald T, Schaller C, Elger CE, 
Kurthen M. Sensory gating in the human hippocampal and rhinal regions. Clinical 
Neurophysiology. 2005;116:1967-1974
[94] Josef Golubic S, Aine C, Supek S. Lack of the neuromagnetic activity in the frontal lobe 
of AD subjects. In: Proceedings of the 6th znanstveni sastanak Hrvatskog fizikalnog 
društva. 2009; Primosten. Zagreb: HFD; 2009. pp. 156-157
[95] Supek S, Golubic SJ, Bryant J, Donahue C, Montaño R, Adair J, Hart B, Knoefel J, Stephen J, 
Aine CJ. Neuromagnetic auditory activity reflects differences between normal aging, 
MCI and AD subjects: An oddball study. Biomagnetism: Transdisciplinary Research 
and Exploration. 2008;1:34-36
[96] Josef Golubic S, Jurasic MJ, Susac A, Huonker R, Gotz T, Haueisen J. Attention modu-
lates topology and dynamics of auditory sensory gating. (Forthcoming; In submission)
[97] Barbas H, Ghashghaei H, Dombrowski SM, Rempel-Clower NL. Medial prefrontal 
cortices are unified by common connections with superior temporal cortices and dis-
tinguished by input from memory-related areas in the rhesus monkey. The Journal of 
Comparative Neurology. 1999;410:343-367
[98] Croxson PL, Johansen-Berg H, Timothy EJ, Behrens M, Robson D, Pinsk MA, Gross 
CG, Richter W, Richter MC, Kastner S, Rushworth MPS. Quantitative investigation of 
connections of the prefrontal cortex in the human and macaque using probabilistic. The 
Journal of Neuroscience. 2005;25:8854-8866
[99] Cavada C, Company T, Tejedor J, Cruz-Rizzolo RJ, Reinoso-Suarez F. The anatomi-
cal connections of the macaque monkey orbitofrontal cortex. Cerebral Cortex. 2000;10: 
220-242
[100] Summerfield C, Egner T. Expectation (and attention) in visual cognition. Trends in 
Cognitive Sciences. 2009;13:403-409
[101] Atkinson RC, Shiffrin RM. Human memory: A proposed system and its control pro-
cesses. In: Spence W, Spence JT, editors. The Psychology of Learning and Motivation. 
Vol. 2. New York: Academic Press; 1968. pp. 89-195
[102] Irimajiri R, Golob EJ, Starr A. Auditory brain-stem, middle- and long-latency evoked 
potentials in mild cognitive impairment. Clinical Neurophysiology. 2005;116(8): 
1918-1929
[103] Thomas C, VomBerg I, Rupp A, Seidl U, Schröder J, Roesch-Ely D. P50 gating deficit in 
Alzheimer dementia correlates to frontal neuropsychological function. Neurobiology 
of Aging. 2010;31:416-424
Biomarker - Indicator of Abnormal Physiological Process192
[104] Cheng CH, Pei-Ning W, Wan-Yu H, Yung-Yang L. Inadequate inhibition of redun-
dant auditory inputs in Alzheimer’s disease: An MEG study. Biological Psychology. 
2012;89:365-373
[105] Bajo R, Maestú F, Nevado A, Sancho M, Gutiérrez R, et al. Functional connectivity in 
mild cognitive impairment during a memory task: Implications for the disconnection 
hypothesis. Journal of Alzheimer's Disease. 2010;22(1):183-193
[106] Takayama Y. A delayed recall battery as a sensitive screening for mild cognitive impair-
ment: Follow-up study of memory clinic patients after 10 years. Journal of Medical and 
Dental Sciences. 2010;57:177-184
[107] Canuet L, Pusil S, López ME, Bajo R, Pineda-Pardo JA, et al. Network disruption and 
cerebrospinal fluid amyloid-beta and phospho-tau levels in mild cognitive impairment. 
Journal of Neuroscience. 2015;35(28):10325-10330
[108] Wu JW, Hussaini SA, Bastille IM, Rodriguez GA, Mrejeru A, et al. Neuronal activ-
ity enhances tau propagation and tau pathology in vivo. Nature Neuroscience. 
2016;9(8):1085-1092
[109] Cuesta P, Garcés P, Castellanos NP, López ME, Aurtenetxe S, et al. Influence of the 
APOE ε4 allele and mild cognitive impairment diagnosis in the disruption of the MEG 
resting state functional connectivity in sources space. Journal of Alzheimer's Disease. 
2015;44(2):493-505
[110] Rapoport SI, Horwitz B, Haxby JV, Grady CL. Alzheimer's disease: Metabolic uncou-
pling of associative brain regions. The Canadian Journal of Neurological Sciences. 
1996;13(4):540-545
[111] Coleman RE. Positron emission tomography diagnosis of Alzheimer’s disease. 
Neuroimaging Clinics of North America. 2005;15:837-846
[112] Klunk WE, Engler H, Nordberg A, Blomqvist G, Holt DP, et al. Imaging brain amy-
loid in Alzheimer’s disease with Pittsburgh compound-B. Annals of Neurology. 
2004;55:306-319
[113] Klupp E, Grimmer T, Tahmasian M, Sorg C, Yakushev I, et al. Prefrontal hypometabo-
lism in Alzheimer disease is related to longitudinal amyloid accumulation in remote 
brain regions. Journal of Nuclear Medicine. 2015;56:399-404
[114] Sharma G, Vijayaraghavan S. Modulation of presynaptic store calcium induces release 
of glutamate and postsynaptic firing. Neuron. 2003;38(6):929-939
Topological Biomarker of Alzheimer’s Disease
http://dx.doi.org/10.5772/intechopen.76633
193

